by jtcir-auto | Mar 15, 2021 | Press Releases
– Company secures next step to continue to build-out pipeline of assets- Company exercised its option to enter into an exclusive license of intellectual property for the development of a proprietary and orally active bacterial vaccine platform technology...
by jtcir-auto | Mar 15, 2021 | Press Releases
– Company secures next step to continue to build-out pipeline of assets- Company exercised its option to enter into an exclusive license of intellectual property for the development of a proprietary and orally active bacterial vaccine platform technology...
by jtcir-auto | Mar 11, 2021 | Press Releases
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential...
by jtcir-auto | Feb 24, 2021 | Press Releases
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr....
by jtcir-auto | Feb 24, 2021 | Press Releases
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr....
by jtcir-auto | Feb 19, 2021 | Press Releases
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...